Bone Biologics completed a preclinical study on its rhNELL-1 growth factor.
Here are four insights:
1. The preclinical study revealed the growth factor successfully encourages bone formation in a phylogenetically advanced spine model.
2. The rhNELL-1 growth factor did not cause inflammation and was well tolerated.
3. Bone Biologics plans to launch a pivotal animal study in mid-2018.
4. The company's rhNELL-1 program is set for human trials in 2019.